Volume 3, Number 4—December 1997
THEME ISSUE
Foodborne
Special Issue
Infectious Disease as an Evolutionary Paradigm
Table 4
Technologies to address microbial threats
| Antibacterial chemotherapy | |
| Potentially unlimited capability; bacterial metabolism and genetic structure notably different from human genome sequencing pointing to bacterial vulnerabilities | |
| Economic-structural factors public expectation for unachievable bargains in safety assurance, cost of development, and ultimate pricing | |
| Dilemmas of regulation of (ab)use | |
| Resurgent interest in bacteriophage and other biologically oriented approaches | |
| Antiviral chemotherapy | |
| Much more difficult program, inherently | |
| Gross underinvestment | |
| New approaches: antisense, ribozymes, targeted D/RNA cleavers | |
| Problematics of sequence-selective targets | |
| Vaccines | |
| Gross underinvestment; other structural problems as above | |
| Liability/indemnification | |
| Vaccination as service to the herd | |
| New approaches: hot biotechnology is coming along especially live attenuated: but testing dilemmas | |
| Safety issues about use of human cells lines; adjuvants | |
| Immunoglobulins and their progeny | |
| Phage display and diversification: biosynthetic antibody | |
| Passive immunization for therapy | |
| Biologic response modifiers | |
| New world of interleukins, cell growth factors so far just scratching surface | |
| Interaction with pathogenesis | |
| Intersection with somatic gene therapy | |
| Technologies for diagnosis and monitoring | |
| Etiologic agents and control | |
| Host polymorphisms and sensitivities | |
| Homely technologies needed | |
| Simple, effective face-masks | |
| Palatable water-disinfectants | |
| Home-use diagnostics of contamination | |
